<p>Royce &amp; Associates LP 在第三季度收购了 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的新头寸，根据其最近向证券交易委员会提交的 13F 表格。该机构投资者收购了 510,000 股该医疗设备公司的股票，价值约为 6,191,000 美元。Royce &amp; Associates LP 在最近的报告期末持有 Tandem Diabetes Care 约 0.75% 的股份。</p>
<p>获取 <strong>Tandem Diabetes Care</strong> 警报：</p>
<p>其他机构投资者和对冲基金最近也调整了对该公司的持股。Amalgamated Bank 在第三季度将其在 Tandem Diabetes Care 的持股增加了 3.5%。Amalgamated Bank 现在拥有 19,617 股该医疗设备公司的股票，价值 238,000 美元，在此期间又购买了 657 股。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Tandem Diabetes Care 的股份增加了 8.8%。宾夕法尼亚州公共学校雇员退休系统现在拥有 17,101 股该医疗设备公司的股票，价值 319,000 美元，在上个季度又购买了 1,384 股。新泽西州警察和消防员退休系统在第二季度将其在 Tandem Diabetes Care 的持股增加了 10.1%。新泽西州警察和消防员退休系统现在拥有 15,299 股该医疗设备公司的股票，价值 285,000 美元，在上个季度又购买了 1,399 股。PNC Financial Services Group Inc. 在第二季度将其在 Tandem Diabetes Care 的股份增加了 8.9%。PNC Financial Services Group Inc. 现在拥有 20,954 股该医疗设备公司的股票，价值 391,000 美元，在上个季度又收购了 1,719 股。最后，Diversified Trust Co 在第三季度将其在 Tandem Diabetes Care 的股份增加了 12.2%。Diversified Trust Co 现在拥有 18,339 股该医疗设备公司的股票，价值 223,000 美元，在上个季度又收购了 1,991 股。</p>
<h2>Tandem Diabetes Care 股价下跌 1.4%</h2>
<p>周四，TNDM 的开盘价为 23.41 美元。该公司的速动比率为 2.02，流动比率为 2.55，债务与股本比率为 2.00。该股票的 50 天移动平均线为 21.42 美元，200 天移动平均线为 17.82 美元。该公司的市值为 16 亿美元，市盈率为 -7.63，贝塔值为 1.63。Tandem Diabetes Care, Inc. 的 52 周低点为 9.98 美元，52 周高点为 29.65 美元。</p>
<p>Tandem Diabetes Care (NASDAQ:TNDM - 获取免费报告) 最近于 2 月 19 日（星期四）公布了季度财报。该医疗设备公司报告本季度每股收益为（0.01）美元，超出市场共识预期的（0.05）美元 0.04 美元。该公司本季度的收入为 2.9038 亿美元，而分析师预期为 2.7714 亿美元。Tandem Diabetes Care 的净利润率为 -20.17%，股本回报率为 -68.23%。与去年同期相比，该公司的收入增长了 15.1%。在去年同期，该公司每股收益为 0.01 美元。分析师预测，Tandem Diabetes Care, Inc. 今年的每股收益将为 -1.68 美元。</p>
<h2>分析师设定新目标价</h2>
<p>TNDM 已成为多份研究报告的主题。巴克莱在 2 月 23 日（星期一）的研究报告中重申了 &#34;增持&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 56.00 美元。Sanford C. Bernstein 在 1 月 9 日（星期五）的研究报告中重申了 &#34;市场表现&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 25.00 美元（上调自 18.00 美元）。瑞穗在 2 月 20 日（星期五）的研究报告中将 Tandem Diabetes Care 的目标价设定为 22.00 美元，并给予该股票 &#34;中性&#34; 评级。Lake Street Capital 在 2 月 23 日（星期一）的研究报告中将 Tandem Diabetes Care 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并将目标价设定为 50.00 美元。最后，瑞银集团在 2 月 20 日（星期五）的报告中重申了 &#34;中性&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 22.00 美元（上调自 17.00 美元）。一位投资分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 28.11 美元。</p>
<p><strong>获取我们最新的 Tandem Diabetes Care 股票报告</strong></p>
<h2>Tandem Diabetes Care 公司简介</h2>
<p>（免费报告）</p>
<p>Tandem Diabetes Care, Inc NASDAQ: TNDM，总部位于加利福尼亚州圣地亚哥，是一家医疗设备公司，专注于为胰岛素依赖型糖尿病患者设计、开发和商业化创新的胰岛素输送系统。公司成立于 2006 年，2011 年推出了首款产品 t:slim® 胰岛素泵，并自此建立了一个包含触摸屏界面、远程软件更新和集成连续血糖监测（CGM）功能的下一代泵的产品组合。</p>
<p>该公司的旗舰产品 t:slim X2® 胰岛素泵，旨在与领先的 CGM 传感器配合使用，并具有根据实时血糖趋势调整基础胰岛素速率的自动胰岛素输送算法。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 Tandem Diabetes Care 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 &#34;防止美联储影响&#34; 你的银行账户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Tandem Diabetes Care 吗？</h2>
<p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tandem Diabetes Care 并不在名单上。</p>
<p>虽然分析师目前对 Tandem Diabetes Care 的评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医药突破 ETF - ALPS

标普健康医疗设备 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

美国医药设备 ETF - iShares

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

TNDM

<p>Royce & Associates LP 已在 Tandem Diabetes Care, Inc. (NASDAQ:TNDM) 中获得了一个新头寸，购买了 510,000 股，价值约为 619 万美元。这项投资占公司总股份的约 0.75%。其他机构投资者也增加了在 Tandem 的持股。该股票开盘价为 23.41 美元，市值为 16 亿美元，市盈率为 -7.63。分析师设定了不同的目标价格，普遍评级为 “持有”，目标价格为 28.11 美元</p>

<p>Royce &amp; Associates LP acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor acquired 510,000 shares of the medical device company's stock, valued at approximately $6,191,000. Royce &amp; Associates LP owned approximately 0.75% of Tandem Diabetes Care at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Royce &amp; Associates LP 在第三季度收购了 Tandem Diabetes Care, Inc. (NASDAQ:TNDM - 免费报告) 的新头寸，根据其最近向证券交易委员会提交的 13F 表格。该机构投资者收购了 510,000 股该医疗设备公司的股票，价值约为 6,191,000 美元。Royce &amp; Associates LP 在最近的报告期末持有 Tandem Diabetes Care 约 0.75% 的股份。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tandem Diabetes Care</strong> 警报：</p>
</div><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. Amalgamated Bank boosted its holdings in Tandem Diabetes Care by 3.5% in the 3rd quarter. Amalgamated Bank now owns 19,617 shares of the medical device company's stock worth $238,000 after buying an additional 657 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Tandem Diabetes Care by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company's stock valued at $319,000 after buying an additional 1,384 shares during the last quarter. Police &amp; Firemen s Retirement System of New Jersey grew its holdings in Tandem Diabetes Care by 10.1% during the 2nd quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company's stock valued at $285,000 after buying an additional 1,399 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Tandem Diabetes Care by 8.9% in the 2nd quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company's stock worth $391,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Diversified Trust Co increased its stake in Tandem Diabetes Care by 12.2% in the 3rd quarter. Diversified Trust Co now owns 18,339 shares of the medical device company's stock worth $223,000 after acquiring an additional 1,991 shares during the last quarter.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也调整了对该公司的持股。Amalgamated Bank 在第三季度将其在 Tandem Diabetes Care 的持股增加了 3.5%。Amalgamated Bank 现在拥有 19,617 股该医疗设备公司的股票，价值 238,000 美元，在此期间又购买了 657 股。宾夕法尼亚州公共学校雇员退休系统在第二季度将其在 Tandem Diabetes Care 的股份增加了 8.8%。宾夕法尼亚州公共学校雇员退休系统现在拥有 17,101 股该医疗设备公司的股票，价值 319,000 美元，在上个季度又购买了 1,384 股。新泽西州警察和消防员退休系统在第二季度将其在 Tandem Diabetes Care 的持股增加了 10.1%。新泽西州警察和消防员退休系统现在拥有 15,299 股该医疗设备公司的股票，价值 285,000 美元，在上个季度又购买了 1,399 股。PNC Financial Services Group Inc. 在第二季度将其在 Tandem Diabetes Care 的股份增加了 8.9%。PNC Financial Services Group Inc. 现在拥有 20,954 股该医疗设备公司的股票，价值 391,000 美元，在上个季度又收购了 1,719 股。最后，Diversified Trust Co 在第三季度将其在 Tandem Diabetes Care 的股份增加了 12.2%。Diversified Trust Co 现在拥有 18,339 股该医疗设备公司的股票，价值 223,000 美元，在上个季度又收购了 1,991 股。</p>
</div><h2>Tandem Diabetes Care Trading Down 1.4%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股价下跌 1.4%</h2>
</div><p>TNDM opened at $23.41 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00. The stock's fifty day moving average is $21.42 and its two-hundred day moving average is $17.82. The company has a market capitalization of $1.60 billion, a P/E ratio of -7.63 and a beta of 1.63. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65.</p>
<div class="lb-trans"><p>周四，TNDM 的开盘价为 23.41 美元。该公司的速动比率为 2.02，流动比率为 2.55，债务与股本比率为 2.00。该股票的 50 天移动平均线为 21.42 美元，200 天移动平均线为 17.82 美元。该公司的市值为 16 亿美元，市盈率为 -7.63，贝塔值为 1.63。Tandem Diabetes Care, Inc. 的 52 周低点为 9.98 美元，52 周高点为 29.65 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $290.38 million during the quarter, compared to analysts' expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The company's revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.01 EPS. Analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care (NASDAQ:TNDM - 获取免费报告) 最近于 2 月 19 日（星期四）公布了季度财报。该医疗设备公司报告本季度每股收益为（0.01）美元，超出市场共识预期的（0.05）美元 0.04 美元。该公司本季度的收入为 2.9038 亿美元，而分析师预期为 2.7714 亿美元。Tandem Diabetes Care 的净利润率为 -20.17%，股本回报率为 -68.23%。与去年同期相比，该公司的收入增长了 15.1%。在去年同期，该公司每股收益为 0.01 美元。分析师预测，Tandem Diabetes Care, Inc. 今年的每股收益将为 -1.68 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>TNDM has been the subject of a number of research reports. Barclays reiterated an &#34;overweight&#34; rating and set a $56.00 target price on shares of Tandem Diabetes Care in a research report on Monday, February 23rd. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating and set a $25.00 price objective (up from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Mizuho set a $22.00 price objective on shares of Tandem Diabetes Care and gave the stock a &#34;neutral&#34; rating in a research note on Friday, February 20th. Lake Street Capital upgraded shares of Tandem Diabetes Care from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $50.00 target price on the stock in a research report on Monday, February 23rd. Finally, UBS Group reaffirmed a &#34;neutral&#34; rating and issued a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $28.11.</p>
<div class="lb-trans"><p>TNDM 已成为多份研究报告的主题。巴克莱在 2 月 23 日（星期一）的研究报告中重申了 &#34;增持&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 56.00 美元。Sanford C. Bernstein 在 1 月 9 日（星期五）的研究报告中重申了 &#34;市场表现&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 25.00 美元（上调自 18.00 美元）。瑞穗在 2 月 20 日（星期五）的研究报告中将 Tandem Diabetes Care 的目标价设定为 22.00 美元，并给予该股票 &#34;中性&#34; 评级。Lake Street Capital 在 2 月 23 日（星期一）的研究报告中将 Tandem Diabetes Care 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并将目标价设定为 50.00 美元。最后，瑞银集团在 2 月 20 日（星期五）的报告中重申了 &#34;中性&#34; 评级，并将 Tandem Diabetes Care 的目标价设定为 22.00 美元（上调自 17.00 美元）。一位投资分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十一位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 28.11 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Tandem Diabetes Care 股票报告</strong></p>
</div><h2>Tandem Diabetes Care Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc NASDAQ: TNDM，总部位于加利福尼亚州圣地亚哥，是一家医疗设备公司，专注于为胰岛素依赖型糖尿病患者设计、开发和商业化创新的胰岛素输送系统。公司成立于 2006 年，2011 年推出了首款产品 t:slim® 胰岛素泵，并自此建立了一个包含触摸屏界面、远程软件更新和集成连续血糖监测（CGM）功能的下一代泵的产品组合。</p>
</div><p>The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.</p>
<div class="lb-trans"><p>该公司的旗舰产品 t:slim X2® 胰岛素泵，旨在与领先的 CGM 传感器配合使用，并具有根据实时血糖趋势调整基础胰岛素速率的自动胰岛素输送算法。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Tandem Diabetes Care 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 &#34;防止美联储影响&#34; 你的银行账户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Tandem Diabetes Care 吗？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Tandem Diabetes Care 并不在名单上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然分析师目前对 Tandem Diabetes Care 的评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Royce & Associates LP Makes New Investment in Tandem Diabetes Care, Inc. $TNDM

Market Beat

Tandem Diabetes

Royce & Associates LP 对 Tandem Diabetes Care, Inc. $TNDM 进行了新的投资